Quality and safety of medication use in primary care: Consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement

BMC Clinical Pharmacology

Volumn 12, Issue , 2012, Pages

  Dreischulte, Tobias ^a   Grant, Aileen M ^b   McCowan, Colin ^b   McAnaw, John J ^c   Guthrie, Bruce ^b  

^a NHS TAYSIDE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

Author keywords

Adverse drug events; Medication error; Preventable drug related morbidity; Primary health care; Quality indicator

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; POTASSIUM; STEROID; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL; VITAMIN D; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASTHMA; BLEEDING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; CONSTIPATION; DIABETES MELLITUS; DIGITALIS INTOXICATION; DRUG EFFICACY; DRUG MONITORING; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENERAL PRACTITIONER; HEALTH CARE PLANNING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MEDICAL EXPERT; MICROALBUMINURIA; NEPHROTOXICITY; OSTEOPOROSIS; PAIN; PATIENT CARE; PATIENT SELECTION; PRIMARY MEDICAL CARE; RAND/UCLA APPROPRIATENESS METHOD; RISK ASSESSMENT; STROKE; THEMATIC ANALYSIS; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; UNITED KINGDOM; VITAMIN SUPPLEMENTATION; CLINICAL PRACTICE; CONSENSUS; DELPHI STUDY; DRUG TOXICITY; HEALTH CARE QUALITY; MEDICATION ERROR; METHODOLOGY; PATIENT SAFETY; PRIMARY HEALTH CARE; VALIDATION STUDY;

CONSENSUS; DELPHI TECHNIQUE; DRUG TOXICITY; GREAT BRITAIN; HUMANS; MEDICATION ERRORS; PATIENT SAFETY; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; QUALITY ASSURANCE, HEALTH CARE; QUALITY IMPROVEMENT;

EID: 84856591749     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-12-5     Document Type: Article

References (55)

1. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. British Journal of Clinical Pharmacology 2006, 63(2):136-147. 2000562, 16803468.
2. Pirmohamed MJ, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004, 329:15-19. 10.1136/bmj.329.7456.15, 443443, 15231615.
3. Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. The Annals of Pharmacotherapy 2007, 41:1411-1426. 10.1345/aph.1H658, 17666582.
4. Winterstein AG SB, Hepler CD, Poole C. Preventable drug related hospital admissions. Ann Pharmacother 2002, 36:1238-1248.
5. National Patient Safety Agency (2006) Improving compliance with oral methotrexate guideline. Available at http://www.nrls.npsa.nhs.uk/resources/?entryid45=59800, National Patient Safety Agency (2006).
6. Medicines and Healthcare Products Regulatory Agency CoHM Antipsychotics: use in elderly people with dementia. Drug Saf Update 2009, 2(8). Medicines and Healthcare Products Regulatory Agency CoHM.
7. Howard R, Avery A, Bissell P. Causes of preventable drug-related hospital admissions: a qualitative study. Qual Saf Health Care 2007, 17:109-116.
8. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: Results of a US Consensus Panel of Experts. Arch Intern Med 2003, 163(22):2716-2724. 10.1001/archinte.163.22.2716, 14662625.
9. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Acove quality indicators. Annals of Internal Medicine 2001, 135(8 Pt 2):653-667.
10. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. International Journal of Clinical Pharmacology & Therapeutics 2008, 46(2):72-83.
11. Instituut vor Verantwoord Medicijngebruik (IVM) Rapport. Benchmark Voorschrijven 2010 (in Dutch). Available at http://www.medicijngebruik.nl/projecten/benchmark-voorschrijven.html, Instituut vor Verantwoord Medicijngebruik (IVM).
12. National Prescribing Service Limited Indicators of Quality Prescribing in Australian General Practice (2006). A manual for users. Available at http://www.nps.org.au/health_professionals/tools/quality_prescribing_indicators_in_australian_general_practice, National Prescribing Service Limited.
13. Wessell AM, Litvin C, Jenkins RG, Nietert PJ, Nemeth LS, Ornstein SM. Medication prescribing and monitoring errors in primary care: a report from the Practice Partner Research Network. Quality & Safety in Health Care 2010, 19(5):e21. 3278747, 22334826.
14. Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of Pharmaceutical care Practice on the practitioner and the patient in the ambulatory care setting: 25 years of experience. Current Pharmaceutical Design 2004, 3987-4001.
15. Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BH. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf 2010, 19(4):319-334.
16. The American College of Cardiology and American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006, 8(9):651-745. The American College of Cardiology and American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation).
17. National Collaborating Centre for Chronic Conditions Atrial fibrillation: National clinical guideline for management in primary and secondary care (update). National Institute for Clinical Excellence, London 2006, Available at http://www.nice.org.uk/nicemedia/live/10982/30055/30055.pdf, National Collaborating Centre for Chronic Conditions.
18. National Collaborating Centre for Chronic Conditions Type 2 Diabetes: National clinical guideline for management in primary and secondary care (update). National Institute for Clinical Excellence, London 2008, Available at http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf, National Collaborating Centre for Chronic Conditions.
19. National Institute for Health and Clinical Excellence Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE Technology appraisal guidance number 161. National Institute for Health and Clinical Excellence, London 2008, Available at http://www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf, National Institute for Health and Clinical Excellence.
20. Scottish Intercollegiate Guidelines Network Acute coronary syndromes. SIGN publication number 93, Edinburgh 2007, Available at http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html, Scottish Intercollegiate Guidelines Network.
21. Scottish Intercollegiate Guidelines Network Management of stable angina. SIGN publication number 96, Edinburgh 2007, Available at http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html, Scottish Intercollegiate Guidelines Network.
22. Scottish Intercollegiate Guidelines Network Management of chronic heart failure. SIGN publication number 95, Edinburgh 2007, Available at http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html, Scottish Intercollegiate Guidelines Network.
23. Scottish Intercollegiate Guidelines Network Risk estimation and the prevention of cardiovascular disease. SIGN publication number 97, Edinburgh 2007, Available at http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html, Scottish Intercollegiate Guidelines Network.
24. Scottish Intercollegiate Guidelines Network British guideline on the management of asthma. SIGN publication number 101. Edinburgh 2008, Available at http://www.sign.ac.uk/guidelines/fulltext/101/index.html, Scottish Intercollegiate Guidelines Network.
25. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure 2008, 10(10):933-989. 10.1016/j.ejheart.2008.08.005, 18826876, The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).
26. Komajda M, Drexler H. Lessons from the European heart survey. Circulation 2006, 113(7):f25-26.
27. Anselmino M, Bartnik M, Malmberg K, Ryden L. Euro Heart Survey I: Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. European Journal of Cardiovascular Prevention & Rehabilitation 2007, 14(1):28-36. 10.1097/01.hjr.0000199496.23838.83, 22325189.
28. Leiter LA, Betteridge DJ, Chacra AR, Chait A, Ferrannini E, Haffner SM, Kadowaki T, Tuomilehto J, Zimmet P, Newman CB, Hey-Hadavi J, Walkinshaw C. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. The British Journal of Diabetes & Vascular Disease 2006, 6(1):31-40.
29. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme--a survey on the quality of care among patients with heart failure in Europe. European Heart Journal 2003, 24(5):442-463.
30. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey J-Y, Prins MH, Levy S, Crijns H. Atrial fibrillation management: a prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. European Heart Journal 2005, 26(22):2422-2434. 10.1093/eurheartj/ehi505, 16204266.
31. Turner S, Thomas M, von Ziegenweidt J, Price D. Prescribing trends in asthma: a longitudinal observational study. Archives of Disease in Childhood 2009, 94(1):16-22. 10.1136/adc.2008.140681, 18701558.
32. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis International 2005, 16(12):2168-2174. 10.1007/s00198-005-2016-z, 16142501.
33. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis International 2004, 15(10):767-778.
34. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW, Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003, 289(9):1107-1116. 10.1001/jama.289.9.1107, 12622580.
35. Stockley's drug interactions. [online]. 2009, Pharmaceutical Press, London, Baxter K.
36. Joint Formulary Committee (British Medical Association and The Royal Pharmaceutical Society of Great Britain) British National Formulary. 2009, 57. London, Joint Formulary Committee (British Medical Association and The Royal Pharmaceutical Society of Great Britain).
37. BMJ Clinical evidence [online]. BMJ Publishing Group Limited, London 2009, Minhas R, Available at http://clinicalevidence.bmj.com/ceweb/index.jsp.
38. National Prescribing Centre Evidence based therapeutics. MeRec monthly 2009, Available at http://www.npc.nhs.uk/merec/, National Prescribing Centre.
39. Medicines and Healthcare products Regulatory Agency (MHRA) and Commission on Human Medicines Drug Safety Update Available at http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/index.htm, Medicines and Healthcare products Regulatory Agency (MHRA) and Commission on Human Medicines.
40. Morris CJ, Cantrill JA. Preventing drug-related morbidity-the development of quality indicators. Journal of Clinical Pharmacy & Therapeutics 2003, 28(4):295-305. 10.1046/j.1365-2710.2003.00496.x, 22334041.
41. Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and applying quality indicators in primary care. BMJ 2003, 326(7393):816-819. 10.1136/bmj.326.7393.816, 1125721, 12689983.
42. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing Care of Vulnerable Elders: Methods for Developing Quality Indicators. Annals of Internal Medicine 2001, 135(8 Part 2):647-652.
43. Kahan JP BS, Leape LL. Measuring the necessity of medical procedures. Med Care 1994, 32(357):-365.
44. Naylor CD. What is appropriate care?. N Engl J Med 1998, 338:1918-1920. 10.1056/NEJM199806253382612, 9637815.
45. Shekelle PG. Are appropriateness criteria ready for use in clinical practice?. NEngl JMed 2001, 344(9):677-678.
46. Brook RH CM, Fink A. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986, 2:53-63. 10.1017/S0266462300002774, 10300718.
47. Leape LL, Park RE, Kahan JP, Brook RH. Group judgements of appropriateness: the effect of panel composition. Quality Assurance Health Care 1992, 4:151-159.
48. Campbell SM, Cantrill JA. Consensus methods in prescribing research. Journal of Clinical Pharmacy & Therapeutics 2001, 26(1):5-14. 10.1046/j.1365-2710.2001.00331.x, 22334041.
49. Morris CJ, Cantrill JA, Hepler CD, Noyce PR. Preventing drug-related morbidity-determining valid indicators. International Journal for Quality in Health Care 2002, 14(3):183-198.
50. Bigby J, Dunn J, Goldman L, Adams JB, Jen P LC, Komaroff AL. Assessing the preventability of emergency hospital admissions. A method for evaluating the quality of medical care in a primary care facility. Am J Med 1987, 83:1031-1036. 10.1016/0002-9343(87)90938-7, 3503572.
51. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med 2001, 31:199-205.
52. Courtman BJ, Stallings SB. Characterisation of drug-related problems in elderly patients on admissions to a medical ward. Can J Hosp Pharm 1995, 48:161-166.
53. Ajzen I. The theory of planned behaviour. Organizational behaviour and human decision processes 1991, 50:170-211.
54. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ 2011, 342:d3514. 10.1136/bmj.d3514, 21693525.
55. Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J, Lazaro P. The RAND/UCLA appropriateness method user's manual. RAND Corporation 2003,